Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Theravance Inc (THRX)    
$27.55 0.90 (3.38%) as of 4:30 Tue 4/22


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 84,767,000 as of 6/30
Market Cap: 2.34(B)
Last Volume: 1,524,710 Avg Vol: 694,331
52 Week Range: $26.47 - $42.64
Level I Sector: Health Care
Level II Sector:   Drugs
Level III Sector:      Biotechnology

Member Indexes:

      

Rankings:

     
Insider 3 Months    : 41.2
Insider 6 Months    : 41.4
Insider 3/6 Months : 83.1
Guru Rank Number :  18
Guru Rank Value     : 23.4
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
 

Company Profile   Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and collaborations with pharmaceutical companies. Co. is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system / pain. Co.'s key programs include: RELVAR™ or BREO™ (fluticasone furoate/vilanterol), ANORO™ (umeclidinium bromide/vilanterol) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist program.

 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 342,229 472,702 3,730,672 14,443,881
Total Buy Value $2,147,483,647 $2,147,483,647 $2,147,483,647 $2,147,483,647
Total People Bought 1 1 1 1
Total Buy Transactions 1 2 4 8
Total Shares Sold 100,806 100,806 647,778 1,003,195
Total Sell Value $3,795,002 $3,795,002 $22,564,705 $32,118,046
Total People Sold 2 2 5 6
Total Sell Transactions 2 2 12 23
End Date 2014-01-23 2013-10-22 2013-04-23 2012-04-23

   
Records found: 420
  Page 1 of 17  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Gunderson Robert V Jr Director   –       •      –    2014-04-17 4 OE $9.69 $249,996 D/D 25,806 109,970     -
   Young William D Director   –       •      –    2014-04-07 4 OE $9.69 $249,996 D/D 25,806 77,935     -
   Waltrip William H Director   –       •      –    2014-03-31 4 OE $9.69 $249,996 D/D 25,806 94,064     -
   Levine Arnold J Director   –       •      –    2014-03-21 4 OE $9.69 $249,996 D/D 25,806 111,794     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2014-03-06 4 OE $12.40 $627,997 D/D 42,153 224,469     -
   Whitesides George M Director   –       •      –    2014-03-06 4 OE $9.69 $249,996 D/D 25,806 600,377     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2014-03-03 4 AS $36.72 $2,417,314 D/D (65,806) 326,731 -28%     
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2014-03-03 4 OE $9.69 $937,488 D/D 96,773 392,537     -
   Blum Leonard M Sr VP, Chief Comm. Officer   •       –      –    2014-02-20 4 D $39.98 $172,354 D/D (4,311) 286,783     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2014-02-20 4 D $39.98 $172,194 D/D (4,307) 182,316     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2014-02-20 4 D $39.98 $172,314 D/D (4,310) 295,764     -
   Lee Junning Sr. VP, Technical Operations   •       –      –    2014-02-20 4 D $39.98 $154,083 D/D (3,854) 148,287     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2014-02-20 4 D $39.98 $171,994 D/D (4,302) 129,475     -
   Winningham Rick E Chief Executive Officer   •       •      –    2014-02-20 4 D $39.98 $371,694 D/D (9,297) 670,763     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2014-02-14 4 AS $39.26 $1,377,688 D/D (35,000) 186,623     -
   Glaxosmithkline Plc 10% Owner   –       –       •   2014-02-11 4 B $12,850,700.00 $2,147,483,647 I/I 342,229 30,258,302 1.5 -30%     
   Lee Junning Sr. VP, Technical Operations   •       –      –    2014-01-23 4 A $0.00 $0 D/D 11,000 152,141     -
   Pasqualone Frank Sr. Vice President, Operations   •       –      –    2014-01-23 4 A $0.00 $0 D/D 20,000 20,000     -
   Lee Junning Sr. VP, Technical OperationsOf   •       –      –    2014-01-06 3 IO $0.00 $0 D/D 0 141,141 -26%     
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2013-11-20 4 D $36.40 $166,312 D/D (4,569) 300,074     -
   Winningham Rick E Chief Executive Officer   •       •      –    2013-11-20 4 D $36.40 $365,674 D/D (10,046) 680,060     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2013-11-20 4 D $36.40 $166,312 D/D (4,569) 222,073     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2013-11-20 4 D $36.40 $166,312 D/D (4,569) 133,777     -
   Glaxosmithkline Plc 10% Owner   –       –       •   2013-10-29 4 B $37.66 $4,913,613 I/I 130,473 29,916,073 1.5 -20%     
   Jonker Jeffrey David Senior VP, Corp. & Bus. Dev.   •       –      –    2013-10-22 4 A $0.00 $0 D/D 15,000 15,000     -

  420 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 17
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed